Cumberland Pharmaceuticals Inc. · NASDAQ:CPIX
Cumberland Pharmaceuticals — Investor Presentation (2026)
14 slides from Cumberland Pharmaceuticals's investor presentation, 2026
Slide 1: Corporate Presentation
Corporate Presentation Nasdaq CPIX
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements Important factors that could cause actual results to differ concerning our product development, our technology, our materially from those indicated by such forward-looking intellectual property, our financial condition and o
Slide 3: Nation's Health Care Capital
Nation’s Health Care Capital 3
Slide 4: Company Overview
Company Overview Innovative biopharmaceutical company Phase II candidates in development with study results milestones Proven record of successful product development 4
Slide 5: Mission & Strategy
Mission & Strategy Mission: Working together to provide unique products that improve the quality of patient care Strategy: We are developing innovative biopharmaceutical brands 5
Slide 6: Ifetroban Overview
Ifetroban Overview • Cumberland’s first new chemical entity • A potent, selective antagonist of thromboxane receptor • Discovered and initially developed by Bristol-Myers Squibb • Safety well-established in 30 clinical studies with over 1,400 subjects • Collaborating with Vanderbilt, Harvard, Scripp
Slide 7: Ifetroban Development Pipeline
Ifetroban Development Pipeline Preclinical IND Phase I Phase II Phase III NDA Dyscorban ® (Duchenne muscular dystrophy) Vasculan ® (Systemic sclerosis) Fibroban ® (Idiopathic Pulmonary Fibrosis) Ifetroban (Cancer metastasis prevention) 7
Slide 8: Duchenne Muscular Dystrophy (DMD)
Duchenne Muscular Dystrophy (DMD) • A rare, fatal, neuromuscular disease with the progressive loss of muscle resulting in deterioration of the skeleton, heart and lungs • Cumberland is investigating ifetroban for the treatment of cardiomyopathy that is associated with DMD • Preclinical data demonstr
Slide 9: Systemic Sclerosis (SSc)
Systemic Sclerosis (SSc) • Debilitating, chronic autoimmune disease causing thickening of the skin and fibrosis of internal organs • Highest death rate of any rheumatic condition • Average survival is approximately 11 years from diagnosis • Women more commonly affected; also occurs in children • No
Slide 10: Fibroban in IPF
Fibroban® in IPF • Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) are a group of disorders that causes irreversible scarring (fibrosis) of lung tissue that leads to lung function decline and early mortality • Idiopathic Pulmonary Fibrosis (IPF) is the most common form of PF-ILDs • Orphan
Slide 11: Slide 11
Slide 12: Collaborating with Academic Research Partners
• Joint initiative to build long term pipeline • Collaborating with Academic Research Partners • Building portfolio of innovative biopharmaceutical candidates • Supporting product development through grant initiatives • Managing Nashville’s Life Science Center • Houses Cumberland’s formulation and t
Slide 13: Cumberland Moving Forward
Cumberland Moving Forward Proven development capabilities Phase II products in development with study results milestones Valuation gap given assets, infrastructure and pipeline 13
Slide 14: NASDAQ: CPIX
NASDAQ: CPIX
Cumberland Pharmaceuticals — Investor Presentation (2026) on 6ix